NCT05239182View on ClinicalTrials.gov

9-ING-41 Plus Retifanlimab and Gemcitabine/Nab-Paclitaxel in Patients With Advanced Pancreatic Adenocarcinoma

PHASE2TerminatedINTERVENTIONAL
Enrollment

7

Participants

Timeline

Start Date

January 26, 2022

Primary Completion Date

December 20, 2022

Study Completion Date

February 4, 2024

Conditions
Pancreatic Adenocarcinoma
Interventions
DRUG

9-ING-41

9-ING-41 is a small molecule potent selective GSK-3β inhibitor

DRUG

Retifanlimab

Humanized, hinge-stabilized, IgG4κ monoclonal antibody that recognizes human PD-1.

DRUG

Gemcitabine

cytotoxic chemotherapy agent

DRUG

Abraxane

cytotoxic chemotherapy agent

Trial Locations (2)

15232

UPMC Hillman Cancer Center, Pittsburgh

66205

Kansas University Cancer Center, Fairway

Sponsors
All Listed Sponsors
collaborator

Actuate Therapeutics Inc.

INDUSTRY

collaborator

Incyte Corporation

INDUSTRY

lead

Anwaar Saeed

OTHER